

OFFICIALLY LICENSED

# BEST OF ASCO®

## 2018 ANNUAL MEETING

6° ANIVERSARIO

4 Y 5 DE  
JULIO  
2018  
CDMX



UNIDAD DE  
CONGRESOS  
DEL IMSS CMN  
SIGLO XXI

[www.congresosmpr.com](http://www.congresosmpr.com)



## Comité Científico



Dra. Guadalupe  
Cervantes Sánchez



Dra. Aura A. Erazo  
Valle Solís

## Reconocimientos por su Trayectoria



Dra. Mariana Chávez  
Mac Gregor  
M.D. Anderson



Dr. Pedro Escudero  
de los Ríos  
CMN Siglo XXI



Dr. Carlos Sánchez  
Basurto

**MEDICAL PHARMA RESEARCH LATAM LLC®** ha seleccionado la Cd. de México, para la realización de eventos académicos de corte internacional, en el área de alta especialidad donde se presentarán los últimos avances en Inmunología Oncológica, Hematología y Síndrome Metabólico.

**MEDICAL PHARMA RESEARCH LATAM LLC®** tiene enfoque en 4 pilares fundamentales:

1. Educación Médica Continua
2. Difusión de lo más novedoso a nivel mundial en nuestro país
3. Enfoque en Médicos Adscritos y Residentes
4. Puntos de Re Certificación

Atentamente:

Comité Científico de MPR LATAM LLC.

Liderazgo en Educación Médica Continua en LATAM

Síguenos en redes sociales:

Facebook, Instagram, Twitter y Youtube - con el hashtag #BESTOFASCOCDMX

## Maestros de Ceremonias



Dra. Brenda Carbajal



Dr. Pabel Miranda Aguirre

## Coordinadores de Módulo

Dr. Jorge Alatorre Alexander - INER  
Dr. Germán Calderillo Ruiz - INCan  
Dra. Guadalupe Cervantes Sánchez - CMN  
20 de Noviembre  
Dr. Carlos Domínguez Reyes - FUCAM  
Dr. Mario Escobar Gómez - Hospital General  
de México

Dr. Miguel Quintana Quintana - Hospital Naval  
Dr. Samuel Rivera Rivera - CMN Siglo XXI  
Dr. Ricardo Villalobos Valencia - CMN LA  
Raza  
Dr. Jorge Robles Aviña - PEMEX

## Profesores Nacionales

Dra. Claudia Arce Salinas - INCan  
Dra. Teresa Bourlon De los Ríos - INCMNSZ  
Dra. Paula Cabrera Galeana - INCan  
Dra. Brenda Carbajal Saldaña - FUCAM  
Dra. Patricia Cortés Esteban - CMN 20 de  
Noviembre  
Dra. Georgina Garnica Jaliffe - Hospital  
General de México  
Dr. Eva Gómez García - COE ISSEMYN  
Dr. César González Morales - Hospital Militar  
Dr. Osvaldo Hernández Flores - HRAE  
Bicentenario  
Dra. Marytere Herrera Martínez - FUCAM  
Dr. David Huitzil Meléndez - INCMNSZ  
Dr. Alejandro Juárez Ramiro - CMN 20 de  
Noviembre  
Dr. Horacio López Basave - INCan  
Dra. Ana Martín Aguilar - CMN Siglo XXI  
Dr. Luis Martínez Barrera - INER

Dra. Gloria Martínez Martínez - CMN Siglo XXI  
Dr. Héctor Martínez Nutes - Hospital General  
de México  
Dr. Rafael Medrano Guzmán - CMN Siglo XXI  
Dr. Pabel Miranda Aguirre - CMN 20 de  
Noviembre  
Dr. Carlos Monroy Álvarez - INR  
Dr. Josué Mora Pérez - Hospital Naval  
Dra. Flavia Morales Vásquez - INCAN/FUCAM  
Dr. David Orta Cortés - Hospital Naval  
Dr. Mario Pérez Martínez - PEMEX  
Dra. Perla Pérez Pérez - CMN 20 de  
Noviembre  
Dr. Jerónimo Rodríguez Cid - Hospital Médica  
Sur  
Dr. Adalberto Toriz José - Hospital Naval  
Dra. Laura Torrecillas Torres - CMN 20 de  
Noviembre  
Dra. Ana Zempoalteca López - FUCAM

## MIÉRCOLES 4 DE JULIO

8:00	Registro	
8:45	Inauguración Presidium: Dra. Erazo Valle, Dra. Nimbe Barroso, Dra. Guadalupe Cervantes Sanchez, Dr. Enrique Bargallo, Dr. Carlos Dominguez, Dr. Gregorio Quintero, Dr. Pedro Escudero, Dr. Sergio Rodríguez Cuevas, Dra. Adela Pointevin, Dr. Francisco Ochoa Carrillo	Dra. Brenda Carbajal - Maestra de Ceremonias
9:00	Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.	Dra. Ana Zempoalteca - FUCAM
9:10	TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node negative breast cancer and an intermediate prognosis 21-gene recurrence score.	Dra. Brenda Carbajal - FUCAM
9:20	PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.	Dra. Marytere Herrera - FUCAM
9:30	Mesa Redonda	Dr. Carlos Domínguez - FUCAM
9:45	Tratamiento de Cáncer de Ovario y Cáncer de Cólon y Recto: entendiendo la complejidad del manejo actual.	Dra. Patricia Cortés - CMN 20 de Nov.
10:35	Coffee Break	
11:05	Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602.	Dra. Flavia Morales Vásquez - INCAN / FUCAM
11:15	Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study.	Dra. Georgina Garnica - Hosp. General de México
11:25	Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.	Dra. Eva Gómez - COE Issemyn
11:35	Mesa Redonda	Dra. Guadalupe Cervantes - CMN 20 de Nov.
11:50	Cáncer de Mama Metastásico RH+ Her2-	Dr. José Adalberto Toriz - Hospital Naval

12:40	Coffee Break / Lunch Box	
13:00	Final analysis of DECOG-SLT trial: No survival benefit for complete lymph node dissection in melanoma patients with positive sentinel node.	Dr. Mario Pérez - PEMEX
13:10	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).	Dr. Mario Pérez - PEMEX
13:20	Mesa Redonda	Dr. Jorge Robles - PEMEX
13:35	Multicenter Phase II Trial of Palbociclib, a Selective Cyclin Dependent Kinase (CDK) 4/6 Inhibitor, and Cetuximab in Platinum-Resistant HPV Unrelated (-) Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC).	Dr. Alejandro Juárez - CMN 20 de Nov.
13:45	A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).	Dr. Héctor Martínez - Hosp. Gral de México
13:55	Mesa Redonda	Dr. Mario Escobar - Hosp Gral de México
14:10	Long-term results of the ADORE trial: adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer.	Dra. Laura Torrecillas - CMN 20 de Nov.
14:20	A Unicancer phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7.	Dr. Horacio López - INCAN
14:30	Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized controlled phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.	Dr. Rafael Medrano - CMN Siglo XXI
14:40	Hammel P, Lacy J, Portales F, et al: Phase II LAPACT trial of nabpaclitaxel plus gemcitabine for patients with locally advanced pancreatic cancer. 2018 Gastrointestinal Cancers Symposium. Abstract 204. Presented January 19, 2018.	Dr. Rafael Medrano - CMN Siglo XXI
14:50	A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).	Dr. David Huitzil - INCMNSZ
15:00	Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial.	Dr. Cesar González - Hosp. Militar
15:10	Mesa Redonda	Dr. Germán Calderillo - INCAN

## JUEVES 5 DE JULIO

7:30	Registro	Dr. Pabel Miranda - Maestro de Ceremonias
9:00	Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3.	Dra. Paula Cabrera - INCAN
9:10	Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.	Dra. Claudia Arce - INCAN
9:20	Mesa Redonda	Dr. Ricardo Villalobos - CMN La Raza
9:35	Nuevo perfil de Eribulina para el tratamiento de cáncer de Mama Metastásico más allá de Antraciclinas y Taxanos.	Dra. Mariana Chávez Mac Gregor - MD Anderson
10:25	Carmena: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial.	Dra. Perla Pérez - CMN 20 de Nov.
10:35	A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial.	Dra. Ana Martín - CMN Siglo XXI
10:45	Keynote-199: pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).	Dra. María Teresa Bourlon - INCMNSZ
10:55	Mesa Redonda	Dr. Samuel Rivera - CMN Siglo XXI
11:10	Coffee Break	
11:40	Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).	Dr. Josué Mora - Hosp. Naval
11:50	Improving Communication with Older Patients with Cancer using Geriatric Assessment (GA): A University of Rochester NCI Community Oncology Research Program (NCORP) Cluster Randomized Controlled Trial (CRCT).	Dr. David Orta - Hosp. Naval
12:00	Randomized Trial of a Symptom Monitoring Intervention for Hospitalized Patients with Cancer.	Dra. Gloria Martínez - CMN Siglo XXI
12:10	Mesa Redonda	Dr. Miguel Quintana - Hosp. Naval

12:25	“Actualidades en el manejo del dolor en el paciente oncológico”	Dr. Carlos Monroy - INR
13:15	Coffee Break / Lunch Box	
13:45	Keynote-407 Phase 3 Study of carboplatin-paclitaxel/ Nab-paclitaxel with or without pembrolizumab for metastatic squamous NSCLC.	Dr. Jeronimo Rodríguez - Hosp. Medica Sur
13:55	Pembrolizumab versus platinum-based chemotherapy as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) $\geq$ 1%; open label , phase 3 KEYNOTE 042- study.	Dr. Luis Martínez - INER
14:05	Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations. NEJ026.	Dr. Osvaldo Hernández - HRAE Bicentenario
14:15	Mesa Redonda	Dr. Jorge Alatorre - INER
14:30	Reconocimiento al Dr. Pedro Escudero de los Ríos, Dr. Carlos Sánchez Basurto y Dra. Mariana Chávez Mac Gregor	Dr. Félix Quijano, Dr. Ernesto Sánchez Forgach
14:50	Cocktail Clausura	

OFFICIALLY LICENSED  
**BEST OF ASCO®**  
2018 ANNUAL MEETING

6<sup>th</sup> Anniversary

